Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life. - Nagot N; Singata-Madliki M; Cournil A; Nalugya J; Tassembedo S; Quillet C; Tonga MW; Tumwine J; Meda N; Kankasa C; Mwiya M; Bangirana P; et al. (Scientific reports, 2021)